UNSPSC 41202073: Respiratory viral panel multiplex nucleic acid assay

In this classification, this entry connotes a device used to perform a Respiratory viral panel multiplex nucleic acid assay. US FDA regulates Respiratory viral panel multiplex nucleic acid assay under 21 CFR 866.3980 and under FDA product code OCC.

UNSPSC 41202073 Respiratory viral panel multiplex nucleic acid assay is a Commodity code covering rapid diagnostic testing kits and laboratory reagents for infectious disease screening—specifically HIV, syphilis, hepatitis B and C, and related pathogen detection—that state and local health departments, criminal justice agencies, and public health facilities procure to support disease surveillance, offender screening, and clinical diagnostic programs. State and local buyers under this code span state departments of public health, county community supervision and criminal justice offices, city public health programs, and university student health centers, with the Illinois Department of Public Health appearing as a repeat buyer conducting multiple emergency procurements for HIV and syphilis testing reagents and instrumentation. The work solicited includes reagent kits and consumables for fully automated or semi-automated analyzer platforms, laboratory testing services bundled with equipment provision, specimen collection and drug screening services that incorporate immunoassay and confirmatory testing (LC/MS/MS or GC/MS), one-time-use rapid test kits, and ancillary testing methodologies including oral fluid and hair analysis. Recent opportunities show vendors are expected to hold CLIA certification, SAMHSA lab accreditation, or equivalent state accreditation, and to provide technical support, preventive maintenance, and rapid turnaround on results.

Recent activity concentrates in Texas and Illinois. The Collin County Community Supervision and Corrections Department issued RFP 2026-327 (due July 23, 2026) for offender specimen collection and drug testing services, estimated at $600,000 annually across two sites with approximately 25,000 tests comprising five- and six-panel immunoassay screens and confirmatory testing. The City of Austin issued IFB 9100AAM1023 (due July 17, 2026) for rapid HIV Type 1 and Type 2 test kits to support the Austin Public Health Program, with volumes of 375 Abbott Determine units and 79 control units annually. The Illinois Department of Public Health conducted emergency procurements in February and May 2026 for HIV and syphilis reagents and instrumentation—including a five-year contract procurement through IFB 26482DPHOFCDIB50489 (due March 16, 2026) for fully automated combination screening assays capable of simultaneous Hepatitis B, C, HIV, and Syphilis testing with approximately 40,500 annual tests across Jackson County. The Texas Department of Criminal Justice issued RFP 696-IG-26-P034 (due May 13, 2026) for forensic analysis services including biological stain identification with DNA testing capabilities, requiring expert witness testimony and ISO/IEC 17025 accreditation. All procurements emphasize firm fixed pricing on a per-test basis, inclusive of freight and staffing, with price redetermination limited to annual anniversaries and pegged to medical Consumer Price Index caps, and evaluation criteria typically weight cost at 30–40 percent alongside technical capability, qualifications, and past performance.